Jakob Magolan
Beyond THC and CBD: The Science and Commerce of Minor Cannabinoids
The race to the highest THC percentage is losing steam. Educated buyers now ask what a product does, not just how strong it is, and that shift is rewr…The race to the highest THC percentage is losing steam. Educated buyers now ask what a product does, not just how strong it is, and that shift is rewriting cannabis market trends across cultivation, retail, and manufacturing. Minor cannabinoids sit a…The race to the highest THC percentage is losing steam. Educated buyers now ask what a product does, not just how strong it is, and that shift is rewriting cannabis market trends across cultivation, retail, and manufacturing. Minor cannabinoids sit at the center of this change. CBG, CBN, CBC, and THCV each bring distinct profiles, from CBN's role in sleep formulations to THCV's appetite and energy associations, backed by a growing body of early s…The race to the highest THC percentage is losing steam. Educated buyers now ask what a product does, not just how strong it is, and that shift is rewriting cannabis market trends across cultivation, retail, and manufacturing. Minor cannabinoids sit at the center of this change. CBG, CBN, CBC, and THCV each bring distinct profiles, from CBN's role in sleep formulations to THCV's appetite and energy associations, backed by a growing body of early scientific and clinical research. This session connects that science to real cannabis industry opportunities. The panelists will break down where the evidence stands today, which compounds are gaining traction, and how to translate them into products that command premium pricing and loyal customers. They’ll explore practical commercialization pathways, from extraction and formulation to positioning and compliant claims, and leave with cannabis business growth strategies you can act on. Show MoreClick the title to see all detailsShow More
